Daraxonrasib nearly doubled overall survival in advanced pancreatic cancer patients during the Phase 3 RASolute 302 clinical trial, prompting the U.S. FDA to accept its New Drug Application for review on July 22, 2026, under an accelerated priority voucher program.
For decades, targeting the RAS pathway in oncology proved notoriously difficult due to the smooth surface of the proteins, which left researchers with few effective binding sites. More than 90% of pancreatic cancers are driven by changes in RAS genes, creating a massive unmet need for effective therapies according to cancer experts. The experimental daily pill daraxonrasib bypasses this traditional structural obstacle by operating as a molecular glue
that binds to a helper protein first, creating a composite surface capable of locking onto both wild-type and mutant RAS proteins.
RASolute 302 Trial Results and Survival Metrics
The global Phase 3 RASolute 302 clinical trial evaluated daraxonrasib monotherapy against standard-of-care cytotoxic chemotherapy in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. In the primary analysis population of patients with RAS G12 mutations, median overall survival reached 13.2 months for those receiving daraxonrasib compared with 6.6 months for patients on chemotherapy, the clinical data showed. That outcome translates to a 60% reduction in the risk of death.
In the broader overall population—which included patients both with and without identified tumor RAS mutations—median overall survival similarly reached 13.2 months with daraxonrasib compared to 6.7 months for the chemotherapy arm. At the 12-month mark, 53.2% of patients in the overall daraxonrasib group remained alive, contrasted with 17.3% in the chemotherapy cohort. The trial met all primary and key secondary endpoints, including significant improvements in progression-free survival.
That presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology sparked widespread enthusiasm among physicians and patients alike, accompanied by a simultaneous publication in The New England Journal of Medicine.
Safety Profile and Patient-Reported Outcomes
Beyond extending life, daraxonrasib demonstrated a more manageable side-effect profile than traditional chemotherapy, which often damages both healthy and cancerous cells. Grade 3 or higher treatment-related adverse events occurred in 43.6% of daraxonrasib patients, compared with 57.5% of those receiving chemotherapy.
Skin rashes and stomatitis, or mouth sores, proved to be the most common adverse events requiring dose reductions for the experimental drug. Medical reporting notes that skin rashes affected more than 86% of patients taking the daily pill. Despite these dermatological side effects, patients reported meaningful preservation of their daily functioning.
Questionnaires administered during the trial indicated that daraxonrasib significantly delayed the deterioration of global health status, quality of life, and cancer-related pain. Patients taking the drug went roughly twice as long before reporting pain or diminished quality of life compared to those undergoing standard chemotherapy.
Regulatory Review Pathways in the United States and Europe
The U.S. Food and Drug Administration accepted the New Drug Application submitted by Revolution Medicines, Inc. on July 22, 2026. Daraxonrasib previously secured both Breakthrough Therapy Designation and Orphan Drug Designation from the agency.
Across the Atlantic, the European Medicines Agency’s Committee for Medicinal Products for Human Use initiated a phased review of the drug, allowing evaluators to assess incoming data prior to the formal submission of a full marketing authorization application. European regulators also granted the drug orphan medicine designation alongside high-priority status under the Cancer Medicines Pathfinder project.
Current Access Options Prior to Final Approval
While formal commercial approval decisions are anticipated later in 2026, patients with advanced pancreatic cancer who cannot participate in clinical trials can access the medicine immediately through an expanded access program.
Keep reading